Citation
Neuzil, Kathleen M., et al. "Immunogenicity and Reactogenicity of 1 Versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine-naive 5-8-year-old Children." The Journal of Infectious Diseases, vol. 194, no. 8, 2006, pp. 1032-9.
Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006;194(8):1032-9.
Neuzil, K. M., Jackson, L. A., Nelson, J., Klimov, A., Cox, N., Bridges, C. B., Dunn, J., DeStefano, F., & Shay, D. (2006). Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. The Journal of Infectious Diseases, 194(8), 1032-9.
Neuzil KM, et al. Immunogenicity and Reactogenicity of 1 Versus 2 Doses of Trivalent Inactivated Influenza Vaccine in Vaccine-naive 5-8-year-old Children. J Infect Dis. 2006 Oct 15;194(8):1032-9. PubMed PMID: 16991077.
TY - JOUR
T1 - Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
AU - Neuzil,Kathleen M,
AU - Jackson,Lisa A,
AU - Nelson,Jennifer,
AU - Klimov,Alexander,
AU - Cox,Nancy,
AU - Bridges,Carolyn B,
AU - Dunn,John,
AU - DeStefano,Frank,
AU - Shay,David,
Y1 - 2006/09/11/
PY - 2006/02/27/received
PY - 2006/05/03/accepted
PY - 2006/9/23/pubmed
PY - 2006/11/15/medline
PY - 2006/9/23/entrez
SP - 1032
EP - 9
JF - The Journal of infectious diseases
JO - J Infect Dis
VL - 194
IS - 8
N2 - BACKGROUND: Two doses of trivalent inactivated influenza vaccine (TIV) are recommended for children <9 years old receiving vaccine for the first time, but compliance is suboptimal. This study assessed the need for a second dose of TIV in this age group. METHODS: In this prospective, open-label study, 232 influenza vaccine-naive 5-8-year-olds enrolled in a health maintenance organization received 2 doses of TIV in fall 2004. Serum for antibody titer measurement was obtained at 3 time points (n = 222). Parents completed diaries for 5 days. RESULTS: Both doses of vaccine were well tolerated. The strongest predictor of a protective antibody response (> or =1 : 40) after 1 dose of TIV was baseline seropositive status. In multivariate analysis adjusting for age, sex, and baseline serostatus, the proportion of children with protective antibody responses was significantly higher after 2 doses than after 1 dose of TIV for each antigen (P < .001, for A/H1N1; P = .01, for A/H3N2; P < .001, for B). Age and sex were not independently predictive of a protective antibody response. Over one-third of children had antibody responses <1:40 for the type B vaccine component, even after 2 doses. CONCLUSIONS: The present study supports the need for 2 doses of TIV in 5-8-year-olds receiving TIV for the first time. Efforts to increase compliance with the 2-dose recommendation are warranted.
SN - 0022-1899
UR - https://www.unboundmedicine.com/medline/citation/16991077/Immunogenicity_and_reactogenicity_of_1_versus_2_doses_of_trivalent_inactivated_influenza_vaccine_in_vaccine_naive_5_8_year_old_children_
L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/507309
DB - PRIME
DP - Unbound Medicine
ER -